Navigation Links
James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30

Xceed Molecular will feature Ziplex automated gene-expression system at the

conference, booth 519

WELLESLEY, Mass., Oct. 28 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that renowned breast cancer researcher and Xceed collaborator, Dr. James L. Wittliff, a professor in the Department of Biochemistry and Molecular Biology at the University of Louisville, will be a featured speaker at the Association for Molecular Pathology (AMP) Annual Meeting. Dr. Wittliff's presentation, "Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex System" is scheduled from 3 to 4 pm on Thursday, October 30, in the Dallas 1-2 Room. The company also announced that it will feature its award-winning Ziplex Automated Gene-Expression System at the conference in booth 519. Currently available for research use only, the Ziplex System is the first integrated system for automated gene-expression analysis. It comprises an automated hybridization workstation, TipChip consumable arrays, reagents, and analysis/reporting software. The AMP 2008 Annual Meeting and Exhibits takes place October 29 through November 2, 2008, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas.

"Visitors to the AMP conference will have a great opportunity to hear Dr. Wittliff's presentation on his exciting research predicting risk of breast cancer recurrence and to learn how the Ziplex System is integral to his study process," said Xceed's President and CEO, David Deems. "The Ziplex System is rapidly becoming the standard platform for the nation's leading institutions performing translational research. Xceed designed the Ziplex System with turnkey functionality and significant advances in automation, array format, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites."

According to Dr. Wittliff, "Advantages of the Ziplex automated system to our research include retention of tissue biopsy custody and the rapid, reproducible analyses of gene subsets to investigate breast cancer behavior in order to identify clinically relevant molecular signatures."

Dr. Wittliff was among the first investigators to prove that the expression of estrogen receptors in breast cancer predicted a patient's response to hormone therapy. This finding led to collaborations with the National Surgical Adjuvant Breast Project (NSABP), establishing Tamoxifen as adjuvant therapy for breast cancer and use of receptor proteins as tissue biomarkers of a patient's prognosis and response. With NEN/Dupont, Dr. Wittliff developed the original FDA-approved kits for assessing receptors in biopsies. His laboratory was designated the National Reference Facility for performing quality assurance (QA) surveys of receptor testing for historical clinical trials in North America and for establishing the College of American Pathologists QA Surveys. In recognition of his contributions to medicine, the University of Innsbruck, Austria, awarded Dr. Wittliff, Doctor of Medicine honoris causa. The American Association for Clinical Chemistry honored him with an award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research; he is also the recipient of the Distinguished Scientist's Award by the Clinical Ligand Assay Society. In 2004, the American Cancer Society recognized his lifetime achievements with the Goldsmith Research Excellence Award. His research team is now working with Xceed to develop clinically related tests for breast and other cancers using its proprietary Ziplex System. Dr. Wittliff's discoveries and development of a unique tumor marker database resulted in the filing of new patents for the University of Louisville and the licensing of his technologies.

About Xceed Molecular (

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the award-winning Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene-expression services, and pre-configured arrays - Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.

SOURCE Xceed Molecular
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
2. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
3. Immunotec Inc. announces appointment of President & CEO James A. Northrop
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. James Webb Space Telescope marks successful completion
6. IRIDEX Announces James Mackaness Will Be Chief Financial Officer
7. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
8. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
9. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
10. Warner Chilcott Reports the Death of Its Director James Andress
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):